Abstract
The molecular mode of action of lonidamine, a therapeutic agent employed in cancer chemotherapy, has been elusive. Here we provide evidence that lonidamine (LND) acts on mitochondria to induce apoptosis. LND provokes a disruption of the mitochondrial transmembrane potential which precedes signs of nuclear apoptosis and cytolysis. The mitochondrial and cytocidal effects of LND are not prevented by inhibitors of caspases or of mRNA or protein synthesis. However, they are prevented by transfection-enforced overexpression of Bcl-2, an oncoprotein which inhibits apoptosis by stabilizing the mitochondrial membrane barrier function. Accordingly, the cell death-inducing effect of LND is amplified by simultaneous addition of PK11195, an isoquinoline ligand of the peripheral benzodiazepine receptor which antagonizes the cytoprotective effect of Bcl-2. When added to isolated nuclei, LND fails to provoke DNA degradation unless mitochondria are added simultaneously. In isolated mitochondria, LND causes the dissipation of the mitochondrial inner transmembrane potential and the release of apoptogenic factors capable of inducing nuclear apoptosis in vitro. Thus the mitochondrion is the subcellular target of LND. All effects of LND on isolated mitochondria are counteracted by cyclosporin A, an inhibitor of the mitochondrial PT pore. We therefore tested the effect of LND on the purified PT pore reconstituted into liposomes. LND permeabilizes liposomal membranes containing the PT pore. This effect is prevented by addition of recombinant Bcl-2 protein but not by a mutant Bcl-2 protein that has lost its apoptosis-inhibitory function. Altogether these data indicate that LND represents a novel type of anti-cancer agent which induces apoptosis via a direct effect on the mitochondrial PT pore.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Angioli R, Janicek M, Sevin BU, Estape R, Averette HE, Koechli OR, Untch M and Penalver M. . 1997 Int. J. Oncol. 11: 777–780.
Backway KL, McCulloch EA, Chow S and Hedley DW. . 1997 Cancer Res. 57: 2446–2451.
Ben-Horin J, Tassini M, Vivi A, Navon G and Kaplan O. . 1995 Cancer Res. 55: 2814–2821.
Bernardi P, Vassanelli S, Veronese P, Colonna R, Szabò I and Zoratti M. . 1992 J. Biol. Chem. 267: 2934–2939.
Bernardi P, Veronese P and Petronilli V. . 1993 J. Biol. Chem. 268: 1005–1010.
Beutner G, Rück A, Riede B, Welte W and Brdiczka D. . 1996 FEBS Lett. 396: 189–195.
Brenner C, Marzo I, de Araujo Vieira HL and Kroemer G. . 1998 Meth. Enzymol. in press.
Brunet CL, Gunby RH, Benson RSP, Hickman JA, Watson AJM and Brady G. . 1998 Cell Death Differ. 5: 107–115.
Bustamante E, Morris HP and Pedersen PL. . 1981 J. Biol. Chem. 256: 8699–8704.
Castiglione S, Kennedy KA, Floridi A and Fiskum G. . 1993 Biochem. Pharmacol. 46: 330–332.
Cheng EHY, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K and Hardwick JM. . 1997 Science 278: 1966–1968.
Connern CP and Halestrap AP. . 1994 Biochem. J. 302: 321–324.
Costantini P, Chernyak BV, Petronilli V and Bernardi P. . 1996 J. Biol. Chem. 271: 6746–6751.
Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R and Kroemer G. . 1997 Cancer Res. 57: 62–67.
DeCesare M, Pratesi G, Giusti A, Polizzi D and Zunino F. . 1998 Br. J. Cancer 77: 434–439.
Del Bufalo D, Biroccio A, Soddu S, Laudonio N, D'Angelo C, Sacchi A and Zupi G. . 1996 J. Clin. Invest. 98: 1165–1173.
DeLena M, Lorusso V, Bottalico C, Brandi M, DeMitrio A, Catino A, Guida M, Latorre A, Leone B, Vallejo C and Cargano G. . 1997 J. Clin. Oncol. 15: 3208–3213.
Dogliotti L, Danese S, Berruti A, Zola P, Buniva T, Bottini A, Richiardi G, Moro G, Farris A, Bau MG and Porcile G. . 1998 Cancer Chemother. Pharmacol. 41: 333–338.
Dudak SD, Lopez A, Block NL and Lokeshwar BL. . 1996 Anticancer Res. 16: 3665–3671.
Fanciulli M, Valentini A, Bruno T, Citro G, Zupi G and Floridi A. . 1996 Oncol. Res. 8: 111–120.
Floridi A, Paggi MG, D'Atri S, Demartino C, Marcante ML, Silvestrini B and Caputo A. . 1981 Cancer Res. 41: 4661–4666.
Fulda S, Sieverts H, Friesen C, Herr I and Debatin KM. . 1997 Cancer Res. 57: 3823–3929.
Fulda S, Susin SA, Kroemer G and Debatin KM. . 1998 Cancer Res. 58: 4453–4460.
Haeffner A, Mollererau B, Deas O, Estaquier J, Mignon A, Haeffner-Cavaillon N, Charpentier B, Senik A and Hirsch F. . 1999 Eur. J. Immunol. in press.
Herr I, Wilhelm D, Bohler T, Angel P and Debatin KM. . 1997 EMBO J. 16: 6200–6208.
Hirsch T, Decaudin D, Susin SA, Marchetti P, Larochette N, Resche-Rigon M and Kroemer G. . 1998 Exp. Cell Res. 241: 426–434.
Jacobson MD, Weil M and Raff MC. . 1997 Cell 88: 347–354.
Kantrow SP and Piantadosi CA. . 1997 Biochem. Biophys. Res. Commun. 232: 669–671.
Kim CN Wang XD, Huang Y, Ibrado AM, Liu L, Fang GF and Bhalla K. . 1997 Cancer Res. 57: 3115–3120.
Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD. . 1997 Science 275: 1132–1136.
Kolesnick RM and Kronke M. . 1998 Annu. Rev. Physiol. 60: 643–665.
Kroemer G. . 1997 Nature Medicine 3: 614–620.
Kroemer G, Bosca L, Zamzami N, Hortelano S and Martinez-A C. . 1997 In The Immunology Methods Manual. Lefkovitz R. (ed.). Academic Press, Chapter 14.2 pp.1111–1125.
Lane DP. . 1992 Nature 358: 15–16.
Liu X, Kim CN, Yang J, Jemmerson R and Wang X. . 1996 Cell 86: 147–157.
Macho A, Hirsch T, Marzo I, Marchetti P, Dallaporta B, Susin SA, Zamzami N and Kroemer G. . 1997 J. Immunol. 158: 4612–4619.
Mancini M, Nicholson DW, Roy S, Thornberry NA, Peterson EP, Casciola-Rosen LA and Rosen A. . 1998 J. Cell Biol. 140: 1485–1495.
Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Haeffner A, Hirsch F, Geuskens M and Kroemer G. . 1996a J. Exp. Med. 184: 1155–1160.
Marchetti P, Hirsch T, Zamzami N, Castedo M, Decaudin D, Susin SA, Masse B and Kroemer G. . 1996b J. Immunol. 157: 4830–4836.
Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A and Kroemer G. . 1996c Cancer Res. 56: 2033–2038.
Marzo I, Brenner C, Zamzami N, Jürgensmeier J, Susin SA, Vieira HLA, Prévost M-C, Xie Z, Mutsiyama S, Reed JC and Kroemer G. . 1998a Science 281: 2027–2031.
Marzo I, Brenner C, Zamzami N, Susin SA, Beutner G, Brdiczka D, Rémy R, Xie Z-H, Reed JC and Kroemer G. . 1998b J. Exp. Med. 187: 1261–1271.
McEnery MW, Snowman AM, Trifiletti RR and Snyder SH. . 1992 Proc. Natl. Acad. Sci. USA 89: 3170–3174.
Miccoli L, Poirson-Bichat F, Sureau F, Bras Conçalves R, Bourgeois Y, Dutrillaux B, Poupon M-F and Oudard S. . 1998 J. Natl. Cancer Inst. 90: 1400–1406.
Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, Magdelénat H, Dutrillaux B and Poupon M-F. . 1995 Int. J. Cancer 62: 216–222.
Pastorino JG, Chen S-T, Tafani M, Snyder JW and Farber JL. . 1998 J. Biol. Chem. 273: 7770–7775.
Petit PX, Goubern M, Diolez P, Susin SA, Zamzami N and Kroemer G. . 1998 FEBS Lett. 426: 111–116.
Petronilli V, Cola C, Massari S, Colonna R and Bernardi P. . 1993 J. Biol. Chem. 268: 21939–21945.
Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B. . 1997 Nature 389: 300–305.
Pratesi G, DeCesare L and Zunino F. . 1996 Cancer Chemother. Pharmacol. 38: 123–128.
Pulselli R, Amadio L, Fanciulli M and Floridi A. . 1996 Anticancer Res. 16: 419–423.
Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M and Reed JC. . 1997 Proc. Natl. Acad. Sci. USA 94: 5113–5118.
Shimizu S, Eguchi Y, Kamiike W, Funahashi Y, Mignon A, Lacronique V, Matsuda H and Tsujimoto Y. . 1998 Proc. Natl. Acad. Sci. USA 95: 1455–1459.
Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M and Kroemer G. . 1996 J. Exp. Med. 184: 1331–1342.
Susin SA, Zamzami N, Castedo M, Daugas E, Wang H-G, Geley S, Fassy F, Reed J and Kroemer G. . 1997a J. Exp. Med. 186: 25–37.
Susin SA, Zamzami N, Larochette N, Dallaporta B, Marzo I, Brenner C, Hirsch T, Petit PX, Geuskens M and Kroemer G. . 1997b Exp. Cell Res. 236: 397–403.
Szabó I, Bernard P and Zoratti M. . 1992 J. Biol. Chem. 267: 2940–2946.
Testi R. . 1996 Trends Biochem. Sci. 21: 468–471.
Thompson CB. . 1995 Science 267: 1456–1462.
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP and Wang X. . 1997 Science 275: 1129–1132.
Zamzami N, Brenner C, Marzo I, Susin SA and Kroemer G. . 1998a Oncogene 16: 2265–2282.
Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B and Kroemer G. . 1995 J. Exp. Med. 182: 367–377.
Zamzami N, Marzo I, Susin SA, Brenner C, Larochette N, Marchetti P, Reed JC, Kofler R and Kroemer G. . 1998b Oncogene 16: 1055–1063.
Zamzami N, Susin SA, Marchetti P, Hirsch T, Gómez-Monterrey I, Castedo M and Kroemer G. . 1996 J. Exp. Med. 183: 1533–1544.
Zoratti M and Szabó I. . 1995 Biochem. Biophys. Acta – Rev. Biomembranes 1241: 139–176.
Acknowledgements
Supported by ANRS, ARC, ARTC, FF, FRM, CNRS, LNC, INSERM, and Sidaction (to GK), Ligue National contre le Cancer, Comité des Hauts-de-Seine (to FH), University of California Breast Cancer Research Program (grant number 1RB-0098), CapCure incorporated (to JCR), and Tobacco-Related Disease Research Program (TDRT 7FT-0092 (to ZX). IM and SAS receive a fellowship from the Spanish Ministry of Sciences and an EC Marie Curie fellowship, respectively.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ravagnan, L., Marzo, I., Costantini, P. et al. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18, 2537–2546 (1999). https://doi.org/10.1038/sj.onc.1202625
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202625
Keywords
This article is cited by
-
Translocator protein 18 kDa: a potential therapeutic biomarker for post traumatic stress disorder
Metabolic Brain Disease (2020)
-
Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis
Arthritis Research & Therapy (2019)
-
The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes
Scientific Reports (2015)
-
The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria
Journal of Bioenergetics and Biomembranes (2014)
-
Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy
British Journal of Cancer (2013)